ImmunOs Therapeutics raises $11 million and further strengthens investor base

“ImmunOs Therapeutics has a very innovative approach to target myeloid checkpoints which are potentially the next major breakthrough in immuno-oncology”

24-Sep-2024 - ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a Series C financing round of $11 million. The ...

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX

15-Jul-2024 - HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture ...

Memo Therapeutics increases Series C financing to CHF 45 million

Proceeds will be used to expand Phase II of best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation

21-May-2024 - Memo Therapeutics AG (or “MTx”) announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. The new funding will be used to bolster the clinical advancement of MTx’s lead ...

Million-euro financial injection for cancer vaccines development

New European and US investors: Nouscom Raises €67.5 million in Oversubscribed Series C Financing Round

15-Nov-2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned ...

Alentis Therapeutics closes $105 million Series C funding

Breakthrough treatments for cancer and fibrotic diseases

18-Apr-2023 - Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical-stage biotech company developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Alentis announced $105 million in Series C financing. The funding round was led by Jeito Capital together with Novo Holdings ...

CatalYm Closes EUR 50 Million Series C Financing

Start-up develops a "new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape"

24-Nov-2022 - CatalYm announced the close of a EUR50 million (USD49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, ...

Cambrian Biopharma Closes $100 Million Series C to Advance Healthspan-boosting Therapeutics to the Clinic

02-Nov-2021 - Cambrian Biopharma, a multi-asset longevity biotech, announced the close of an oversubscribed Series C financing, which raised $100 million. The financing was co-led by Anthos Capital and SALT Fund, with participation from existing investors Apeiron Investment Group, Future Ventures, Moore ...

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

Proceeds will be Used to Accelerate Advancement of Pipeline of Multispecific Antibodies in Oncology

26-May-2021 - Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new ...

Drug discovery with artificial intelligence

Evotec participates in Exscientia's financing round

29-May-2020 - Evotec SE announced that the Company has participated in the Series C funding round of Exscientia, the Artificial Intelligence (AI)-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors’ consortium consisting of Evotec, ...

OMEICOS Therapeutics Closes €17m Series C Financing

Advancing lead candidate towards pivotal trials

05-Nov-2018 - OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, announced the closing of a EUR 17 million (approx. USD 19.5 million) Series C financing led by new ...